Hysterectomy and uterine fibroids; Leiomyoma; Myoma
Uterine fibroids, also called leimyomas or myomas, are non-cancerous growths that originate in the muscular wall of the uterus. Fibroids are the most common type of tumor found in female reproductive organs.
Symptoms of Uterine Fibroids
Many women with fibroids do not have any symptoms. When symptoms do occur, they may include:
Women without symptoms do not need treatment, but they should be evaluated regularly by their doctors. Women with symptoms from their fibroids have many options for treatment, including drugs and surgery. Women with symptoms from their fibroids have many options for treatment, including drugs and surgery.
Fibroids usually shrink after menopause, so many women close to menopause (average age 51) choose to defer treatment.
FDA Warns Against Power Morcellation
In 2014, the FDA issued a safety alert discouraging the use of laparoscopic power morcellation during myomectomy or hysterectomy for uterine fibroids. The power morcellator is a medical device used to cut up fibroids or the uterus into tiny fragments for easier removal. There is evidence that this procedure may spread cancer in women who have undetected uterine cancer.
A uterine fibroid (known medically as a leiomyoma or myoma) is a noncancerous (benign) growth of smooth muscle and connective tissue. Fibroids can range in size from as small as a pinhead to larger than a melon. Fibroids have been reported weighing more than 20 pounds.
Fibroids originate from the thick wall of the uterus and are categorized by where they grow:
The primary structures in the reproductive system include:
The inner lining of the uterus is called the endometrium. During pregnancy this inner lining thickens and becomes enriched with blood vessels to house and support the growing fetus. If pregnancy does not occur, the endometrium is shed as part of the menstrual flow. Menstrual flow also consists of blood and mucus from the cervix and vagina.
Reproductive Hormones: The hypothalamus (an area in the brain) and the pituitary gland regulate the reproductive hormones. The pituitary gland is often referred to as the master gland because of its important role in many vital functions, many of which require hormones.
In women, six key hormones serve as chemical messengers that regulate the reproductive system:
It is not clear what causes fibroids, but estrogen and progesterone appear to play a major role in their growth. Fibroids tend to shrink after menopause, when estrogen levels decline.
Uterine fibroids are the most common tumor found in female reproductive organs.
Fibroids are most common in women from their 30s through early 50s. (After menopause, fibroids tend to shrink.) About 20 to 40% of women age 35 and older have fibroids of significant enough size to cause symptoms.
Uterine fibroids are particularly common in African American women, and these women tend to develop them at a younger age than white women. Fibroids in African American women are usually larger at the time of diagnosis than those in white women, and tend to cause more severe symptoms.
Family history (having a mother or sister who had fibroids) may increase risk.
Obesity and high blood pressure may possibly be associated with increased fibroid risk.
Most fibroids appear to have only a small effect on a woman's fertility. Female infertility is usually due to other factors than fibroids.
Fibroids may increase pregnancy complications and delivery risks. These may include:
Anemia due to iron deficiency can develop if fibroids cause excessive bleeding. Small, submucosal fibroids are most likely to cause abnormally heavy bleeding.
Most cases of anemia are mild and can be treated with dietary changes and iron supplements. However, prolonged and severe anemia that is not treated can cause heart problems.
Fibroids can press and squeeze the bladder, leading to frequent need for urination (urge urinary incontinence).
Large fibroids that press against the bladder occasionally result in urinary tract infections. Pressure on the ureters may cause urinary tract obstruction and kidney damage.
Pressure on the bowels may result in constipation.
Any fibroid has the rare potential to be cancerous (malignant). However the vast majority of fibroids are noncancerous (benign). Fibroids after menopause have the highest risk of being cancerous. Women who are postmenopausal need to have careful monitoring of their fibroids. Doctors often recommend removing any growing fibroid after menopause.
Many women with fibroids do not have symptoms. When they do, symptoms may include:
Doctors can detect some fibroids as masses (lumps) during a pelvic exam. During a pelvic exam, the doctor will check for pregnancy-related conditions and other conditions, such as ovarian cysts. The doctor will ask you about your medical history, particularly as it relates to menstrual bleeding patterns. Other causes of abnormal uterine bleeding must also be considered.
Ultrasound is the standard imaging technique for detecting uterine fibroids. The doctor will order transabdominal and transvaginal ultrasounds. Ultrasound is a painless technique that uses sound waves to image the uterus and ovaries. In transabdominal ultrasound, the ultrasound probe is moved over the abdominal area. In transvaginal ultrasound, the probe is inserted into the vagina.
A variation of ultrasound, called hysterosonography, uses ultrasound along with saline (salt water) infused into the uterus to enhance the visualization of the uterus.
Hysteroscopy is a procedure that may be used to detect the presence of fibroids, polyps, or other causes of bleeding originating from the inside of the uterine cavity. It may also be used during surgical procedures to remove fibroids.
Hysteroscopy can be performed in a doctor's office or in a hospital setting. The procedure uses a long flexible tube called a hysteroscope, which is inserted into the vagina and through the cervix to reach the uterus. A fiber-optic light source and a tiny camera in the tube allow the doctor to view the cavity. The uterus is filled with saline or carbon dioxide to inflate the cavity and provide better viewing. This can cause cramping.
Hysteroscopy is non-invasive and does not require incisions. Local, regional, or general anesthesia is typically given.
In some cases, laparoscopic surgery may be performed as a diagnostic procedure. Laparoscopy involves inserting a fiber-optic scope into a small incision made near the navel. Whereas hysteroscopy allows the doctor to view inside the uterus, laparoscopy provides a view of the outside of the uterus, including the ovaries, fallopian tubes, and general pelvic area.
In certain cases, the doctor may perform an endometrial biopsy to determine if there are abnormal cells in the lining of the uterus that suggest cancer. Endometrial biopsy can be performed in a doctor's office, with or without anesthesia. Dilation & curettage (D&C) is a more invasive procedure that involves scraping the inside lining of the uterus. It can be used to take tissue samples and also as a procedure to help temporarily reduce heavy menstrual bleeding.
The doctor may also order a complete blood count (CBC) to check for signs of anemia.
Almost all women, at some time in their reproductive life, experience heavy bleeding during menstrual periods.
A number of conditions can cause or contribute to the risk:
Many women with uterine fibroids do not require treatment. A woman's age and the severity of her symptoms are important factors in considering treatment options.
The three treatment options are:
Women should discuss each option with their doctor. Deciding on a particular surgical procedure depends on the location, size, and number of fibroids. Certain procedures affect a woman's fertility and are recommended only for women who are past childbearing age or who do not want to become pregnant. In terms of surgical options, myomectomy is generally the only commonly performed procedure that preserves fertility.
For fibroid pain relief, women can use acetaminophen (Tylenol, generic) or nonsteroidal anti-inflammatory drugs (NSAIDS) such as ibuprofen (Motrin, Advil, generic) or naproxen (Aleve, generic).
Prescription drug treatment of fibroids uses medicines that block or suppress estrogen, progesterone, or both hormones.
Oral contraceptives (OCs) are sometimes used to control the heavy menstrual bleeding associated with fibroids, but they do not reduce fibroid growth. Newer types of continuous-dosing OCs reduce or eliminate the number of periods a woman has per year.
Intrauterine devices (IUDs) that release progestin can help reduce heavy bleeding. Specifically, the levonorgestrel-releasing intrauterine system, or LNG-IUS (Mirena), has shown excellent results. It is approved by the FDA to treat heavy menstrual bleeding. However, in rare cases the presence of fibroids may cause the IUD to be expelled from the uterus.
Gonadotropin-releasing hormone (GnRH) agonists include the implant goserelin (Zoladex), a monthly injection of leuprolide (Lupron Depot, generic), and the nasal spray nafarelin (Synarel). GnRH agonists block the release of the reproductive hormones LH (luteinizing hormone) and FSH (follicle-stimulating hormone). As a result, the ovaries stop ovulating and producing estrogen. Basically, GnRH agonists induce a temporary menopause.
GnRH agonists may be used as drug treatment to shrink fibroids in women who are approaching the age of menopause. They may also be used as a preoperative treatment 3 to 4 months before fibroid surgery to reduce fibroid size so that a more minimally invasive surgical procedure can be performed.
Commonly reported side effects, which can be severe in some women, include menopausal-like symptoms. These symptoms include:
The side effects vary in intensity, but typically resolve within 1 month after stopping the medication.
The most important concern is possible osteoporosis from estrogen loss. Women should not take these drugs for more than 6 months.
GnRH treatments used alone do not prevent pregnancy. Furthermore, if a woman becomes pregnant during their use, there is some risk for birth defects.
A myomectomy surgically removes only the fibroids and leaves the uterus intact, which helps preserve fertility. Myomectomy may also help regulate abnormal uterine bleeding caused by fibroids. Not all women are candidates for myomectomy. If the fibroids are numerous or large, myomectomy can become complicated, resulting in increased blood loss. If cancer is found, conversion to a full hysterectomy may be necessary.
To perform a myomectomy, the surgeon may use a standard "open" surgical approach (laparotomy) or less invasive ones (hysteroscopy or laparoscopy).
Complications: The risks for myomectomy are generally the same of those for other surgical procedures, including bleeding and infection.
Laparoscopic power morcellation is a procedure that uses a tool to cut up uterine fibroids into tiny pieces to be removed through a small incision in the abdomen. There is evidence that power morcellation may spread cancerous tissue in women with fibroids who have undetected uterine cancer. The FDA advises against the use of laparoscopic power morcellators for myomectomy or hysterectomy procedures.
Recurrence of Fibroids: Myomectomy is not necessarily a permanent solution for fibroids. They can recur after these procedures.
Uterine artery embolization (UAE), also called uterine fibroid embolization (UFE), is a relatively new way of treating fibroids. UAE deprives fibroids of their blood supply, causing them to shrink.
UAE is a minimally invasive radiology treatment and is technically a nonsurgical therapy. It is less invasive than hysterectomy and myomectomy, and involves a shorter recovery time than the other procedures. The patient remains conscious, although sedated, during the procedure, which takes around 60 to 90 minutes.
The procedure is typically performed in the following manner:
Effect on Fertility: In general, UAE is considered an option for only those who have completed childbearing. The American College of Obstetricians and Gynecologists advises women who wish to have children that it is not yet known how this procedure affects their potential for becoming pregnant.
Complications: Compared to other procedures, women who have UAE miss fewer days of work. Serious complications occur in less than 0.5% of cases. In addition to potential impact on fertility, other postoperative effects may include.
Success Rates: Uterine artery embolization is very effective and most women are very satisfied with the results. Menorrhagia symptoms, as well as pelvic pain and urinary symptoms, improve in 85 to 95% of women within 3 months after treatment. However, some women may have fibroid recurrence and may need future procedures (repeat embolization or hysterectomy).
Some studies suggest that women with larger single fibroids or larger uteruses are not good candidates for UAE.
Uterine artery embolization does not remove fibroid tissue. In the rare cases of sarcoma (cancer cells in the muscles of the uterus), this procedure may delay diagnosis and therefore worsen prognosis.
Endometrial ablation destroys the lining of the uterus (the endometrium) and is usually performed to stop heavy menstrual bleeding. It may also be used to treat women with small fibroids. It is not helpful for large fibroids or for fibroids that have grown outside of the interior uterine lining. For most women, this procedure stops the monthly menstrual flow. In some women, menstrual flow is not stopped but is significantly reduced.
Most endometrial ablation procedures use some form of heat (radiofrequency, heated fluid, microwave) to destroy the uterine lining. The procedure is typically done on an outpatient basis and can take as few as 10 minutes to perform. Recovery generally takes a few days, although watery or bloody discharge can last for several weeks.
Endometrial ablation significantly decreases the likelihood a woman will become pregnant. However, pregnancy can still occur and this procedure increases the risks of complications, including miscarriage. Women who have this procedure must be committed to not becoming pregnant and to using birth control.
A main concern of endometrial ablation is that it may delay or make it more difficult to diagnose uterine cancer in the future. (Postmenopausal bleeding or irregular vaginal bleeding can be warning signs of uterine cancer.) Women who have endometrial ablation still have a uterus and cervix, and should continue to have recommended Pap smears and pelvic exams.
MRgFUS is a non-invasive procedure that uses high-intensity ultrasound waves to heat and destroy (ablate) uterine fibroids. This “thermal ablation” procedure is performed with a device, the ExAblate, which combines magnetic resonance imaging (MRI) with ultrasound.
During the 3-hour procedure, the patient lies inside an MRI machine. The patient receives a mild sedative to help relax but remains conscious throughout the procedure. The radiologist uses the MRI to target the fibroid tissue and direct the ultrasound beam. The MRI also helps the radiologist monitor the temperature generated by the ultrasound.
MRgFUS is appropriate only for women who have completed childbearing or who do not intend to become pregnant. The procedure cannot treat all types of fibroids. Fibroids that are located near the bowel and bladder, or outside of the imaging area, cannot be treated.
This procedure is relatively new, and long-term results are not yet available. Likewise, it requires an extensive period of time involving MRI equipment. Many insurance companies consider this procedure investigational, experimental, and unproven and do not pay for this treatment.
Hysterectomy is the surgical removal of the uterus. The ovaries may also be removed, although this is not necessary for fibroid treatment. Hysterectomy is a permanent solution for fibroids, and is an option if other treatments have not worked or are not appropriate.
A woman cannot become pregnant after having a hysterectomy. If the ovaries are removed along with the uterus, hysterectomy causes immediate menopause.
Once a decision for a hysterectomy has been made, the patient should discuss with her doctor what will be removed. The common choices are:
Hysterectomy procedures include:
Total Abdominal Hysterectomy: Total abdominal hysterectomy (TAH) has been the traditional procedure. It is an invasive procedure that is is best suited for women with large fibroids, when the ovaries also need to be removed, or when cancer or pelvic disease is present.
The surgeon makes a 5- to 7-inch incision in the lower part of the belly. The cut may either be vertical, or it may go horizontally across the abdomen, just above the pubic hair (a bikini cut). The bikini cut incision heals faster and is less noticeable than a vertical incision, which is used in more complicated cases. The patient may need to remain in the hospital for 3 to 4 days, and recuperation at home takes about 4 to 6 weeks.
Vaginal Hysterectomy, LAVH, and Total Laparoscopic Hysterectomy: Newer minimally invasive procedures have become the preferred methods for hysterectomy. The American College of Obstetricians and Gynecologists (ACOG) recommends vaginal hysterectomy as the first choice, when possible. Vaginal hysterectomy requires only a vaginal incision through which the uterus is removed. The vaginal incision is closed with stitches.
ACOG recommends laparoscopic hysterectomy as the second choice for minimally invasive procedures. Laparoscopic hysterectomies use a laparoscope to help guide and perform the surgery. The laparoscope is a thin flexible tube through which a tiny video camera and surgical instruments are inserted.
A variation of the vaginal approach is called laparoscopic-assisted vaginal hysterectomy (LAVH). It uses several small abdominal incisions through which the surgeon severs the attachments to the uterus and, if needed, ovaries. In LAVH, the uterus (and ovaries) is then removed through the vaginal incision, as in the standard vaginal approach. In total laparoscopic hysterectomy, they are removed in small pieces through the abdomen. The FDA discourages the use of laparoscopic power morcellation with hysterectomy (see below in “Complications”.)
Vaginal hysterectomy, LAVH, total laparoscopic hysterectomy, and robotic-assisted laparoscopic hysterectomy have fewer complications, shorter hospital stays, and faster recovery times than abdominal hysterectomy.
Robotic Hysterectomy: Robotic-assisted hysterectomy is a type of laparoscopic hysterectomy, but the surgical instruments are attached to a robot. The surgeon uses a computer console in the operating room to guide the robot's movements.
The American College of Obstetricians and Gynecologists (ACOG) advises that robotic hysterectomy is best suited for complex hysterectomies. Before choosing robotic hysterectomy, it is important to find a surgeon who has extensive training and experience with this technique.
Minor complications after hysterectomy are very common. About half of women develop minor and treatable urinary tract infections. There is usually mild pain and light vaginal bleeding post operation. More serious complications are uncommon but can include infection and blood clots.
Power Morcellation: Laparoscopic power morcellation is a procedure that is sometimes used during laparoscopic hysterectomy or myomectomy. The power morcellator is a cutting device that breaks up the uterus into smaller fragments that can be removed through small abdominal incisions.
In 2014, the FDA discouraged the use of laparoscopic power morcellation because of evidence that this procedure can spread cancer through the pelvis and abdomen in women who have undetected uterine sarcoma, a type of uterine cancer. About 1 in 350 women who undergo hysterectomy or myomectomy for uterine fibroids have this type of cancer.
Power morcellators should never be used in women who are peri- or post-menopausal, or in women who have suspected or known uterine cancer. Younger women who are considering a fibroid procedure using power morcellation should discuss with their doctors all possible risks.
Ask a family member or friend to help out for the first few days at home. The following are some of the precautions and tips for postoperative care:
Women who have had abdominal hysterectomies should discuss with their doctors when exercise programs more intense than walking can be started. The abdominal muscles are important for supporting the upper body, and recovering strength may take a long time. Even after the wound has healed, the patient may have an on-going feeling of overall weakness, for some time. Some women do not feel completely well for as long as a year while others may recover in only a few weeks.
If a woman has had her cervix removed, she no longer needs annual Pap smears. However, women who have had any type of hysterectomy should continue to receive routine pelvic and breast exams, and mammograms.
Surgical removal of the ovaries causes immediate menopause. If the ovaries are not removed, they will usually continue to secrete hormones until the natural age of menopause (average age 51 years), even after the uterus is removed.
Because hysterectomy removes the uterus, a woman will no longer experience menstrual periods, even if she has not become menopausal. Studies show that women who have had hysterectomies become menopausal on average 1 to 3 years earlier than would naturally occur.
Your doctor may recommend you take hormone therapy (HT) after your hysterectomy. Women who have had a hysterectomy are given estrogen-only therapy (ET), which may be administered as pills or as a skin patch that releases the hormone into the bloodstream. It can also be given “locally” to treat specific symptoms such as vaginal dryness (see below). Hot flashes and vaginal dryness are the most common menopausal symptoms. Hot flashes are often more severe after surgical menopause than in menopause that occurs naturally.
Sexual intercourse may resume 6 to 12 weeks following surgery. The effect of hysterectomy on sexuality varies among women. Most studies show no negative impact on sexuality after hysterectomy. A small percentage of women notice a negative impact on their sex drive or response. Other women report increased sexual drive and pleasure because they are free from the problems that prompted hysterectomy.
A vaginal lubricant can help reduce vaginal dryness. Your doctor can also prescribe a low-dose vaginal estrogen treatment, which is applied directly the vagina. Topical vaginal estrogen is available in a cream, tablet, or ring that is inserted into the vagina.
American College of Obstetricians and Gynecologists. ACOG practice bulletin. Alternatives to hysterectomy in the management of leiomyomas. Obstet Gynecol. 2008 Aug;112(2 Pt 1):387-400.
American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 110: Noncontraceptive uses of hormonal contraceptives. Obstet Gynecol. 2010 Jan;115(1):206-18.
American College of Obstetricians and Gynecologists. Power morcellation and occult malignancy in gynecologic surgery: a special report. May 2014. Available at: www.acog.org/Resources-And-Publications/Task-Force-and-Work-Group-Reports/Power-Morcellation-and-Occult-Malignancy-in-Gynecologic-Surgery. Accessed September 15, 2014.
American College of Obstetricians and Gynecologists.Statement on Robotic Surgery by ACOG President James T. Breeden, MD. Published March 14, 2013. Available at: www.acog.org/About_ACOG/News_Room/News_Releases/2013/Statement_on_Robotic_Surgery. Accessed August 20, 2013.
Bulun SE. Uterine fibroids. N Engl J Med. 2013 Oct 3;369(14):1344-55.
Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion; Centers for Disease Control and Prevention (CDC), Farr S, Folger SG, Paulen M, et al. U S. Medical Eligibility Criteria for Contraceptive Use, 2010: adapted from the World Health Organization Medical Eligibility Criteria for Contraceptive Use, 4th edition. MMWR Recomm Rep. 2010 Jun 18;59(RR-4):1-86.
Edwards RD, Moss JG, Lumsden MA, Wu O, Murray LS, Twaddle S, et al. Uterine-artery embolization versus surgery for symptomatic uterine fibroids. N Engl J Med. 2007 Jan 25;356(4):360-70.
Goodwin SC, Spies JB. Uterine fibroid embolization. N Engl J Med. 2009 Aug 13;361(7):690-7.
Gupta JK, Sinha A, Lumsden MA, Hickey M. Uterine artery embolization for symptomatic uterine fibroids. Cochrane Database Syst Rev. 2012 May 16;5:CD005073.
Hickey M and Kaunitz AM. Hormonal contraception. In: Melmed S, Polonsky, KS, Larsen PR, and Kronenberg HM, eds. Williams Textbook of Endocrinology. 12th ed. St. Louis, MO: WB Saunders; 2011; chap 18.
Homer H, Saridogan E. Uterine artery embolization for fibroids is associated with an increased risk of miscarriage. Fertil Steril. 2010 Jun;94(1):324-30. Epub 2009 Apr 9.
Kaunitz AM, Meredith S, Inki P, Kubba A, Sanchez-Ramos L. Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis. Obstet Gynecol. 2009 May;113(5):1104-16.
Kho KA, Nezhat CH(2). Evaluating the risks of electric uterine morcellation. JAMA. 2014 Mar 5;311(9):905-6.
Moorman PG, Myers ER, Schildkraut JM, Iversen ES, Wang F, Warren N. Effect of hysterectomy with ovarian preservation on ovarian function. Obstet Gynecol. 2011 Dec;118(6):1271-9.
Moss J, Cooper K, Khaund A, Murray L, Murray G, Wu O, et al. Randomised comparison of uterine artery embolisation (UAE) with surgical treatment in patients with symptomatic uterine fibroids (REST trial): 5-year results. BJOG. 2011 Jul;118(8):936-944. Epub 2011 Apr 12.
Peddada SD, Laughlin SK, Miner K, et al. Growth of uterine leiomyomata among premenopausal black and white women. Proc Natl Acad Sci USA. 2008 Dec 16;105(50):19887-92. Epub 2008 Dec 1.
Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol. 2009 May;113(5):1027-37.
Perera HK, Ananth CV, Richards CA, Neugut AI, Lewin SN, Lu YS, et al. Variation in ovarian conservation in women undergoing hysterectomy for benign indications. Obstet Gynecol. 2013 Apr;121(4):717-26.
Stokes LS, Wallace MJ, Godwin RB, Kundu S, Cardella JF;Society of Interventional Radiology Standards of Practice Committee. Quality improvement guidelines for uterine artery embolization for symptomatic leiomyomas. J Vasc Interv Radiol. 2010 Aug;21(8):1153-63. Epub 2010 Jun 16.
Stout MJ, Odibo AO, Graseck AS, Macones GA, Crane JP, Cahill AG. Leiomyomas at routine second-trimester ultrasound examination and adverse obstetric outcomes. Obstet Gynecol. 2010 Nov;116(5):1056-63.
U.S. Food and Drug Administration. FDA warns against using laparoscopic power morcellators to treat uterine fibroids. Posted 11/24/2014. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm424435.htm. Accessed December 2, 2014.
U.S. Food and Drug Administration. Laparoscopic power morcellation in hysterectomy and myomectomy: FDA safety communication: Use discouraged due to increased risk in women with uterine fibroids. Posted 4/17/14. www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm393809.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery. Accessed September 15, 2014.
van der Kooij SM, Bipat S, Hehenkamp WJ, Ankum WM, Reekers JA. Uterine artery embolization versus surgery in the treatment of symptomatic fibroids: a systematic review and metaanalysis. Am J Obstet Gynecol. 2011 Oct;205(4):317.e1-18. Epub 2011 Mar 16.
Wright JD, Ananth CV, Lewin SN, Burke WM, Lu YS, Neugut AI, et al. Robotically assisted vs laparoscopic hysterectomy among women with benign gynecologic disease. JAMA. 2013 Feb 20;309(7):689-98.
Wright JD, Tergas AI, Burke WM, Cui RR, Ananth CV, Chen L, et al. Uterine Pathology in Women Undergoing Minimally Invasive Hysterectomy Using Morcellation. JAMA. 2014 Jul 22. [Epub ahead of print]
Last reviewed on: 12/2/2014
Reviewed by: Cynthia D. White, MD, Fellow American College of Obstetricians and Gynecologists, Group Health Cooperative, Bellevue, WA. Also reviewed by David Zieve, MD, MHA, Isla Ogilvie, PhD, and the A.D.A.M. Editorial team. Author: Julia Mongo, MS.